Repaglinide
Repaglinide is an approved active ingredient.
Chemical compound
What it is used for
- Maturity-onset diabetes of the young type 2
- Diabetes
- Type 2 diabetes
Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.
How it works
- Sulfonylurea receptor 1, Kir6.2 blocker
Common side effects
The following serious adverse reaction is also described elsewhere in the labeling: Hypoglycemia The most common adverse reactions (5% or greater incidence) among patients treated with repaglinide were: hypoglycemia, upper respiratory infection, headache, sinusitis, arthralgia, nausea, diarrhea, and back pain.
Who should not take it
Repaglinide tablets are contraindicated in patients with: Concomitant use of gemfibrozil Known hypersensitivity to repaglinide or any inactive ingredients Concomitant use with gemfibrozil Known hypersensitivity to repaglinide or any inactive ingredients
Pregnancy and breastfeeding
Limited available data from case reports and case series with repaglinide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Interactions
- Ciclosporin
- Clarithromycin
- Clopidogrel
- Clozapine
- Deferasirox
- Epinephrine
- Erythromycin
- Fluoxetine
- Glucagon
- Isoniazid
- Leflunomide
- Montelukast
- Octreotide
- Olanzapine
- Pentoxifylline
- Rifampicin
- Salbutamol
- Spironolactone
- Terbutaline
- Teriflunomide
- Trimethoprim
Brand names
United States
Prandin
European Union
Enyglid · NovoNorm · Prandin · Repaglinide Krka · Repaglinide Teva
Canada
Auro-Repaglinide · Jamp Repaglinide · Sandoz Repaglinide
Other trade names
Repaglinide accord
Approval status
- US Food and Drug Administration
- prescription · since 1997
- European Medicines Agency
- authorised · since 1998
- Health Canada
- prescription · marketed
- First approval anywhere
- 1997
Codes
- ATC
- A10BX02
- RxNorm CUI
- 73044
- ChEMBL
- CHEMBL1272
- PubChem CID
- 65981
- UNII
- 668Z8C33LU
- Wikidata
- Q2195995
Frequently asked questions
What is Repaglinide used for?
Repaglinide is used for: Maturity-onset diabetes of the young type 2, Diabetes, and Type 2 diabetes.
What are the brand names of Repaglinide?
Brand names of Repaglinide include Prandin, Enyglid, NovoNorm, Repaglinide Krka, Repaglinide Teva, Auro-Repaglinide, Jamp Repaglinide, and Sandoz Repaglinide.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)